Comparative Pharmacology
Head-to-head clinical analysis: POHERDY versus TOPICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POHERDY versus TOPICORT.
POHERDY vs TOPICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
POHERDY is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), binding to domain IV of the extracellular segment, thereby inhibiting ligand-independent HER2 signaling and mediating antibody-dependent cellular cytotoxicity (ADCC).
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing production of prostaglandins and leukotrienes, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
POHERDY: No approved drug. No dosing available.
Apply a thin film to the affected skin areas twice daily. Maximum adult dose: 50 g/week. Not for use on the face, axillae, or groin. Do not use under occlusive dressings.
None Documented
None Documented
Terminal half-life 12–18 hours (mean 15 h); requires dose adjustment in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life: 2-4 hours for parent drug; clinical effect lasts longer due to receptor binding
Renal: 60% unchanged; fecal/biliary: 30%; 10% metabolized
Renal (metabolites): ~75%; Fecal: ~25%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid